TY - JOUR
T1 - Health-related quality of life in patients surviving non-small cell lung cancer
AU - Grutters, Janneke P. C.
AU - Joore, Manuela A.
AU - Wiegman, Erwin M.
AU - Langendijk, Johannes A.
AU - de Ruysscher, Dirk
AU - Hochstenbag, Monique
AU - Botterweck, Anita
AU - Lambin, Philippe
AU - Pijls-Johannesma, Madelon
PY - 2010/10
Y1 - 2010/10
N2 - Background and aims The EuroQol 5D (EQ-5D) is a standardised instrument for measuring health-related quality of life (HRQoL). It provides a utility score for health, and a self-rating of HRQoL (EQ-VAS). In this study, the EQ-5D was used to assess HRQoL in survivors of non-small cell lung cancer (NSCLC). The influence of tumour stage, adverse events, initial treatment and presence of recurrence was examined. Methods Patients treated for NSCLC were sent a questionnaire, consisting of the EQ-5D, EQ-VAS and questions regarding adverse events. Tumour stage, date and type of initial treatment, and presence of recurrence were derived from patient files once patients had completed the questionnaire and informed consent form. Influencing factors were examined by exploring subgroups and using multiple regression analysis. Results Of the 374 patients contacted, 260 (70%) returned a completed questionnaire. The EQ-VAS generated an average self-rated health of 69 (SD 18). The mean utility score was 0.74 (SD 0.27). Respondents with severe adverse events (dyspnoea grade >= 3) had statistically significantly lower utility scores than respondents without severe adverse events (median 0.52 vs 0.81; p
AB - Background and aims The EuroQol 5D (EQ-5D) is a standardised instrument for measuring health-related quality of life (HRQoL). It provides a utility score for health, and a self-rating of HRQoL (EQ-VAS). In this study, the EQ-5D was used to assess HRQoL in survivors of non-small cell lung cancer (NSCLC). The influence of tumour stage, adverse events, initial treatment and presence of recurrence was examined. Methods Patients treated for NSCLC were sent a questionnaire, consisting of the EQ-5D, EQ-VAS and questions regarding adverse events. Tumour stage, date and type of initial treatment, and presence of recurrence were derived from patient files once patients had completed the questionnaire and informed consent form. Influencing factors were examined by exploring subgroups and using multiple regression analysis. Results Of the 374 patients contacted, 260 (70%) returned a completed questionnaire. The EQ-VAS generated an average self-rated health of 69 (SD 18). The mean utility score was 0.74 (SD 0.27). Respondents with severe adverse events (dyspnoea grade >= 3) had statistically significantly lower utility scores than respondents without severe adverse events (median 0.52 vs 0.81; p
U2 - 10.1136/thx.2010.136390
DO - 10.1136/thx.2010.136390
M3 - Article
C2 - 20861294
SN - 0040-6376
VL - 65
SP - 903
EP - 907
JO - Thorax
JF - Thorax
IS - 10
ER -